In a major shift for how mental health conditions might be treated, the US Food and Drug Administration (FDA) has approved ...
Swedish neurotech startup Flow Neuroscience has secured FDA approval for the first brain stimulation device for home use in ...
A noninvasive, home-based brain treatment with transcranial direct current stimulation (tDCS) can reduce pain severity, improve pain-related disability, and enhance endogenous pain modulation in women ...
Please provide your email address to receive an email when new articles are posted on . High-definition transcranial direct current stimulation was well tolerated with mild adverse effects. The ...
The U.S. Food and Drug Administration cleared Flow Neuroscience’s at-home electrical stimulation headset for adults with moderate-to-severe depression A trial of 174 people found the device led to ...
HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NXL) (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office ...
Amanda Ellison does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...
The FDA has approved the first at -home brain-stimulation device for adults with major depressive disorder (MDD). The FL-100 transcranial direct-current stimulation (tDCS) system (Flow Neuroscience) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results